APO Research
Talk to an analyst

APO RESEARCH · REPORT

Nedaplatin for Injection

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Nedaplatin for Injection Market Outlook and Growth Opportunities 2026

27 December 2025191 pages

Choose your research edition.

Industry ResearchNedaplatin for Injection Industry Research Report 2026111 pages · $2,950 USDIndustry Growth & TrendsGlobal Nedaplatin for Injection Industry Growth and Trends Forecast to 203276 pages · $3,450 USDMarket StructureGlobal Nedaplatin for Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032174 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nedaplatin for Injection Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Nedaplatin for Injection Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Nedaplatin for Injection market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Nedaplatin for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Nedaplatin for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Nedaplatin for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Nedaplatin for Injection market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Nedaplatin for Injection market include Simcere Pharmaceutical Group Limited, Qilu Pharmaceutical, Jiangsu Aosaikang Pharmaceutical Co., Ltd. and Jilin Hengjin Pharmaceutical Co., Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Nedaplatin for Injection market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Nedaplatin for Injection and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Nedaplatin for Injection sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Nedaplatin for Injection market size, projected growth trends, production technologies, key applications, and end-use industries.

Nedaplatin for Injection Segment by Company

Simcere Pharmaceutical Group Limited

Qilu Pharmaceutical

Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Jilin Hengjin Pharmaceutical Co., Ltd.

Nedaplatin for Injection Segment by Type

20mg

10mg

Others

Nedaplatin for Injection Segment by Application

Hospital

Clinic

Other

Nedaplatin for Injection Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Nedaplatin for Injection status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Nedaplatin for Injection market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Nedaplatin for Injection significant trends, drivers, influence factors in global and regions.

6. To analyze Nedaplatin for Injection competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nedaplatin for Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nedaplatin for Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nedaplatin for Injection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Nedaplatin for Injection market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Nedaplatin for Injection industry.

Chapter 3: Detailed analysis of Nedaplatin for Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Nedaplatin for Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Nedaplatin for Injection in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Nedaplatin for Injection Industry Trends Table 2. Nedaplatin for Injection Industry Drivers Table 3. Nedaplatin for Injection Industry Opportunities and Challenges Table 4. Nedaplatin for Injection Industry Restraints Table 5. Global Nedaplatin for Injection Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Nedaplatin for Injection Revenue Share by Company (2021-2026) Table 7. Global Nedaplatin for Injection Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Nedaplatin for Injection Sales Volume Share by Company (2021-2026) Table 9. Global Nedaplatin for Injection Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Nedaplatin for Injection Company Ranking, (2024-2026) & (USD Million) Table 11. Global Nedaplatin for Injection Key Company Manufacturing Base & Headquarters Table 12. Global Nedaplatin for Injection Company, Product Type & Application Table 13. Global Nedaplatin for Injection Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Nedaplatin for Injection by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 20mg Table 18. Significant Companies of 10mg Table 19. Significant Companies of Others Table 20. Global Nedaplatin for Injection Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Nedaplatin for Injection Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Nedaplatin for Injection Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Nedaplatin for Injection Sales Volume Share by Type (2021-2026) Table 24. Global Nedaplatin for Injection Sales Volume Share by Type (2027-2032) Table 25. Global Nedaplatin for Injection Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Nedaplatin for Injection Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Nedaplatin for Injection Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Nedaplatin for Injection Sales Value Share by Type (2021-2026) Table 29. Global Nedaplatin for Injection Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Hospital Table 31. Significant Companies of Clinic Table 32. Significant Companies of Other Table 33. Global Nedaplatin for Injection Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Nedaplatin for Injection Sales Volume by Application (2021-2026) & (K Units) Table 35. Global Nedaplatin for Injection Sales Volume by Application (2027-2032) & (K Units) Table 36. Global Nedaplatin for Injection Sales Volume Share by Application (2021-2026) Table 37. Global Nedaplatin for Injection Sales Volume Share by Application (2027-2032) Table 38. Global Nedaplatin for Injection Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Nedaplatin for Injection Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Nedaplatin for Injection Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Nedaplatin for Injection Sales Value Share by Application (2021-2026) Table 42. Global Nedaplatin for Injection Sales Value Share by Application (2027-2032) Table 43. Global Nedaplatin for Injection Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Nedaplatin for Injection Sales by Region (2021-2026) & (K Units) Table 45. Global Nedaplatin for Injection Sales Market Share by Region (2021-2026) Table 46. Global Nedaplatin for Injection Sales by Region (2027-2032) & (K Units) Table 47. Global Nedaplatin for Injection Sales Market Share by Region (2027-2032) Table 48. Global Nedaplatin for Injection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Nedaplatin for Injection Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Nedaplatin for Injection Sales Value Share by Region (2021-2026) Table 51. Global Nedaplatin for Injection Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Nedaplatin for Injection Sales Value Share by Region (2027-2032) Table 53. Global Nedaplatin for Injection Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Nedaplatin for Injection Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Nedaplatin for Injection Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global Nedaplatin for Injection Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Nedaplatin for Injection Sales by Country (2021-2026) & (K Units) Table 58. Global Nedaplatin for Injection Sales Market Share by Country (2021-2026) Table 59. Global Nedaplatin for Injection Sales by Country (2027-2032) & (K Units) Table 60. Global Nedaplatin for Injection Sales Market Share by Country (2027-2032) Table 61. Global Nedaplatin for Injection Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Nedaplatin for Injection Sales Value Market Share by Country (2021-2026) Table 63. Global Nedaplatin for Injection Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Nedaplatin for Injection Sales Value Market Share by Country (2027-2032) Table 65. Simcere Pharmaceutical Group Limited Company Information Table 66. Simcere Pharmaceutical Group Limited Business Overview Table 67. Simcere Pharmaceutical Group Limited Nedaplatin for Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Simcere Pharmaceutical Group Limited Nedaplatin for Injection Product Portfolio Table 69. Simcere Pharmaceutical Group Limited Recent Development Table 70. Qilu Pharmaceutical Company Information Table 71. Qilu Pharmaceutical Business Overview Table 72. Qilu Pharmaceutical Nedaplatin for Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Qilu Pharmaceutical Nedaplatin for Injection Product Portfolio Table 74. Qilu Pharmaceutical Recent Development Table 75. Jiangsu Aosaikang Pharmaceutical Co., Ltd. Company Information Table 76. Jiangsu Aosaikang Pharmaceutical Co., Ltd. Business Overview Table 77. Jiangsu Aosaikang Pharmaceutical Co., Ltd. Nedaplatin for Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Jiangsu Aosaikang Pharmaceutical Co., Ltd. Nedaplatin for Injection Product Portfolio Table 79. Jiangsu Aosaikang Pharmaceutical Co., Ltd. Recent Development Table 80. Jilin Hengjin Pharmaceutical Co., Ltd. Company Information Table 81. Jilin Hengjin Pharmaceutical Co., Ltd. Business Overview Table 82. Jilin Hengjin Pharmaceutical Co., Ltd. Nedaplatin for Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Jilin Hengjin Pharmaceutical Co., Ltd. Nedaplatin for Injection Product Portfolio Table 84. Jilin Hengjin Pharmaceutical Co., Ltd. Recent Development Table 85. Key Raw Materials Table 86. Raw Materials Key Suppliers Table 87. Nedaplatin for Injection Distributors List Table 88. Nedaplatin for Injection Customers List Table 89. Research Programs/Design for This Report Table 90. Authors List of This Report Table 91. Secondary Sources Table 92. Primary Sources List of Figures Figure 1. Nedaplatin for Injection Product Image Figure 2. Global Nedaplatin for Injection Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Nedaplatin for Injection Sales Value (2021-2032) & (US$ Million) Figure 4. Global Nedaplatin for Injection Sales (2021-2032) & (K Units) Figure 5. Global Nedaplatin for Injection Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Nedaplatin for Injection Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 20mg Image Figure 10. 10mg Image Figure 11. Others Image Figure 12. Global Nedaplatin for Injection Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Nedaplatin for Injection Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Nedaplatin for Injection Sales Volume Share by Type (2021-2032) Figure 15. Global Nedaplatin for Injection Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Nedaplatin for Injection Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Nedaplatin for Injection Sales Value Share by Type (2021-2032) Figure 18. Hospital Image Figure 19. Clinic Image Figure 20. Other Image Figure 21. Global Nedaplatin for Injection Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Nedaplatin for Injection Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Nedaplatin for Injection Sales Volume Share by Application (2021-2032) Figure 24. Global Nedaplatin for Injection Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Nedaplatin for Injection Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Nedaplatin for Injection Sales Value Share by Application (2021-2032) Figure 27. Global Nedaplatin for Injection Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global Nedaplatin for Injection Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Nedaplatin for Injection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Nedaplatin for Injection Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Nedaplatin for Injection Sales Value (2021-2032) & (US$ Million) Figure 32. North America Nedaplatin for Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Nedaplatin for Injection Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Nedaplatin for Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Nedaplatin for Injection Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Nedaplatin for Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Nedaplatin for Injection Sales Value (2021-2032) & (US$ Million) Figure 38. South America Nedaplatin for Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Nedaplatin for Injection Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Nedaplatin for Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Nedaplatin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Nedaplatin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Nedaplatin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Nedaplatin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Nedaplatin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Nedaplatin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Nedaplatin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Nedaplatin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Nedaplatin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Nedaplatin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Nedaplatin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Nedaplatin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Nedaplatin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Nedaplatin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Nedaplatin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Nedaplatin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Nedaplatin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Nedaplatin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Nedaplatin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Nedaplatin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Nedaplatin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Nedaplatin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Nedaplatin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Nedaplatin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Nedaplatin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Nedaplatin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Nedaplatin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Nedaplatin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Nedaplatin for Injection Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Nedaplatin for Injection Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • 20mg
  • 10mg
  • Others
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Simcere Pharmaceutical Group Limited
  • Qilu Pharmaceutical
  • Jiangsu Aosaikang Pharmaceutical Co., Ltd.
  • Jilin Hengjin Pharmaceutical Co., Ltd.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Nedaplatin for Injection Sales Value (2021-2032)
  4. 1.2.2 Global Nedaplatin for Injection Sales Volume (2021-2032)
  5. 1.2.3 Global Nedaplatin for Injection Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Nedaplatin for Injection Market Dynamics
  1. 2.1 Nedaplatin for Injection Industry Trends
  2. 2.2 Nedaplatin for Injection Industry Drivers
  3. 2.3 Nedaplatin for Injection Industry Opportunities and Challenges
  4. 2.4 Nedaplatin for Injection Industry Restraints
3 Nedaplatin for Injection Market by Company
  1. 3.1 Global Nedaplatin for Injection Company Revenue Ranking in 2025
  2. 3.2 Global Nedaplatin for Injection Revenue by Company (2021-2026)
  3. 3.3 Global Nedaplatin for Injection Sales Volume by Company (2021-2026)
  4. 3.4 Global Nedaplatin for Injection Average Price by Company (2021-2026)
  5. 3.5 Global Nedaplatin for Injection Company Ranking (2024-2026)
  6. 3.6 Global Nedaplatin for Injection Company Manufacturing Base and Headquarters
  7. 3.7 Global Nedaplatin for Injection Company Product Type and Application
  8. 3.8 Global Nedaplatin for Injection Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Nedaplatin for Injection Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Nedaplatin for Injection Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Nedaplatin for Injection Market by Type
  1. 4.1 Nedaplatin for Injection Type Introduction
  2. 4.1.1 20mg
  3. 4.1.2 10mg
  4. 4.1.3 Others
  5. 4.2 Global Nedaplatin for Injection Sales Volume by Type
  6. 4.2.1 Global Nedaplatin for Injection Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Nedaplatin for Injection Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Nedaplatin for Injection Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Nedaplatin for Injection Sales Value by Type
  10. 4.3.1 Global Nedaplatin for Injection Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Nedaplatin for Injection Sales Value by Type (2021-2032)
  12. 4.3.3 Global Nedaplatin for Injection Sales Value Share by Type (2021-2032)
5 Nedaplatin for Injection Market by Application
  1. 5.1 Nedaplatin for Injection Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global Nedaplatin for Injection Sales Volume by Application
  6. 5.2.1 Global Nedaplatin for Injection Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Nedaplatin for Injection Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Nedaplatin for Injection Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Nedaplatin for Injection Sales Value by Application
  10. 5.3.1 Global Nedaplatin for Injection Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Nedaplatin for Injection Sales Value by Application (2021-2032)
  12. 5.3.3 Global Nedaplatin for Injection Sales Value Share by Application (2021-2032)
6 Nedaplatin for Injection Regional Sales and Value Analysis
  1. 6.1 Global Nedaplatin for Injection Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Nedaplatin for Injection Sales by Region (2021-2032)
  3. 6.2.1 Global Nedaplatin for Injection Sales by Region: 2021-2026
  4. 6.2.2 Global Nedaplatin for Injection Sales by Region (2027-2032)
  5. 6.3 Global Nedaplatin for Injection Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Nedaplatin for Injection Sales Value by Region (2021-2032)
  7. 6.4.1 Global Nedaplatin for Injection Sales Value by Region: 2021-2026
  8. 6.4.2 Global Nedaplatin for Injection Sales Value by Region (2027-2032)
  9. 6.5 Global Nedaplatin for Injection Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Nedaplatin for Injection Sales Value (2021-2032)
  12. 6.6.2 North America Nedaplatin for Injection Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Nedaplatin for Injection Sales Value (2021-2032)
  15. 6.7.2 Europe Nedaplatin for Injection Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Nedaplatin for Injection Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Nedaplatin for Injection Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Nedaplatin for Injection Sales Value (2021-2032)
  21. 6.9.2 South America Nedaplatin for Injection Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Nedaplatin for Injection Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Nedaplatin for Injection Sales Value Share by Country, 2025 VS 2032
7 Nedaplatin for Injection Country-level Sales and Value Analysis
  1. 7.1 Global Nedaplatin for Injection Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Nedaplatin for Injection Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Nedaplatin for Injection Sales by Country (2021-2032)
  4. 7.3.1 Global Nedaplatin for Injection Sales by Country (2021-2026)
  5. 7.3.2 Global Nedaplatin for Injection Sales by Country (2027-2032)
  6. 7.4 Global Nedaplatin for Injection Sales Value by Country (2021-2032)
  7. 7.4.1 Global Nedaplatin for Injection Sales Value by Country (2021-2026)
  8. 7.4.2 Global Nedaplatin for Injection Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Nedaplatin for Injection Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Nedaplatin for Injection Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Nedaplatin for Injection Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Nedaplatin for Injection Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Nedaplatin for Injection Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Nedaplatin for Injection Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Nedaplatin for Injection Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Nedaplatin for Injection Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Nedaplatin for Injection Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Nedaplatin for Injection Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Nedaplatin for Injection Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Nedaplatin for Injection Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Nedaplatin for Injection Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Nedaplatin for Injection Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Nedaplatin for Injection Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Nedaplatin for Injection Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Nedaplatin for Injection Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Nedaplatin for Injection Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Nedaplatin for Injection Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Nedaplatin for Injection Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Nedaplatin for Injection Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Nedaplatin for Injection Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Nedaplatin for Injection Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Nedaplatin for Injection Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Nedaplatin for Injection Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Nedaplatin for Injection Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Nedaplatin for Injection Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Nedaplatin for Injection Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Nedaplatin for Injection Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Nedaplatin for Injection Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Simcere Pharmaceutical Group Limited
  2. 8.1.1 Simcere Pharmaceutical Group Limited Company Information
  3. 8.1.2 Simcere Pharmaceutical Group Limited Business Overview
  4. 8.1.3 Simcere Pharmaceutical Group Limited Nedaplatin for Injection Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Simcere Pharmaceutical Group Limited Nedaplatin for Injection Product Portfolio
  6. 8.1.5 Simcere Pharmaceutical Group Limited Recent Developments
  7. 8.2 Qilu Pharmaceutical
  8. 8.2.1 Qilu Pharmaceutical Company Information
  9. 8.2.2 Qilu Pharmaceutical Business Overview
  10. 8.2.3 Qilu Pharmaceutical Nedaplatin for Injection Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Qilu Pharmaceutical Nedaplatin for Injection Product Portfolio
  12. 8.2.5 Qilu Pharmaceutical Recent Developments
  13. 8.3 Jiangsu Aosaikang Pharmaceutical Co., Ltd.
  14. 8.3.1 Jiangsu Aosaikang Pharmaceutical Co., Ltd. Company Information
  15. 8.3.2 Jiangsu Aosaikang Pharmaceutical Co., Ltd. Business Overview
  16. 8.3.3 Jiangsu Aosaikang Pharmaceutical Co., Ltd. Nedaplatin for Injection Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Jiangsu Aosaikang Pharmaceutical Co., Ltd. Nedaplatin for Injection Product Portfolio
  18. 8.3.5 Jiangsu Aosaikang Pharmaceutical Co., Ltd. Recent Developments
  19. 8.4 Jilin Hengjin Pharmaceutical Co., Ltd.
  20. 8.4.1 Jilin Hengjin Pharmaceutical Co., Ltd. Company Information
  21. 8.4.2 Jilin Hengjin Pharmaceutical Co., Ltd. Business Overview
  22. 8.4.3 Jilin Hengjin Pharmaceutical Co., Ltd. Nedaplatin for Injection Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Jilin Hengjin Pharmaceutical Co., Ltd. Nedaplatin for Injection Product Portfolio
  24. 8.4.5 Jilin Hengjin Pharmaceutical Co., Ltd. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Nedaplatin for Injection Value Chain Analysis
  2. 9.1.1 Nedaplatin for Injection Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Nedaplatin for Injection Sales Mode & Process
  6. 9.2 Nedaplatin for Injection Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Nedaplatin for Injection Distributors
  9. 9.2.3 Nedaplatin for Injection Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst